Exploiting the curative potential of adoptive T‐cell therapy for cancer

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works

Cancer Genome Landscapes

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · see citing works

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · see citing works

Coordinated regulation of myeloid cells by tumours

Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · see citing works

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Flaherty, K. T., Puzanov, I. J., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,542 · see citing works

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · see citing works

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · see citing works

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,542 · see citing works

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C. L., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,500 · see citing works

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,389 · see citing works

Epstein–Barr virus: 40 years on

Young, L. S., & Rickinson, A. B. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1452 · Cited by 2,230 · see citing works

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · see citing works

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,145 · see citing works

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · see citing works

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043 · see citing works

A human memory T cell subset with stem cell–like properties

Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · see citing works

Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766 · see citing works

Human papillomavirus oncoproteins: pathways to transformation

Moody, C. A., & Laimins, L. A. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2886 · Cited by 1,757 · see citing works

Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1

Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., Fakhry, C., Xie, T., Zhang, J., Wang, J., et al. (2011) · Science · doi:10.1126/science.1206923 · Cited by 1,697 · see citing works

Adoptive immunotherapy for cancer: harnessing the T cell response

Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688 · see citing works

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C.-H., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,635 · see citing works

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D., Marić, I., Stetler‐Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2011) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,441 · see citing works

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421 · see citing works

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337 · see citing works

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

Dudley, M. E., Yang, J. C., Sherry, R. M., Hughes, M. S., Royal, R. E., Kammula, U. S., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,334 · see citing works

The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues

Hammarström, S. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0119 · Cited by 1,303 · see citing works

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L. A., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,183 · see citing works

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Morgan, R. A., Chinnasamy, N., Abate‐Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,155 · see citing works

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3515 · Cited by 1,093 · see citing works

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

Robbins, P. F., Lu, Y., El‐Gamil, M., Li, Y. F., Gross, C. A., Gartner, J. J., Lin, J., Teer, J. K., Cliften, P. F., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,074 · see citing works

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells

Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,063 · see citing works

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

Parkhurst, M. R., Yang, J. C.-H., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,025 · see citing works

Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth‐Dreese, F. A., Dellemijn, T. A. M., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 927 · see citing works

Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience

Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915 · see citing works

Structural alterations of the epidermal growth factor receptor gene in human gliomas.

Wong, A. J., Ruppert, J. M., Bigner, S. H., Grzeschik, C. H., Humphrey, P. A., Bigner, D. S., & Vogelstein, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2965 · Cited by 851 · see citing works

Tumor-specific Th17-polarized cells eradicate large established melanoma

Muranski, P. J., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 838 · see citing works

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

Berger, C., Jensen, M. C., Lansdorp, P. M., Gough, M., Elliott, C., & Riddell, S. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32103 · Cited by 822 · see citing works

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells

Gallina, G., Dolcetti, L., Serafini, P., Santo, C. D., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28828 · Cited by 792 · see citing works

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

Heslop, H. E., Slobod, K. S., Pulè, M. A., Hale, G. A., Rousseau, A., Smith, C. A., Bollard, C. M., Liu, H., Wu, M.-F., Rochester, R., et al. (2009) · Blood · doi:10.1182/blood-2009-08-239186 · Cited by 780 · see citing works

CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

Antony, P. A., Piccirillo, C. A., Akpınarlı, A., Finkelstein, S. E., Speiss, P. J., Surman, D. R., Palmer, D. C., Chan, C., Klebanoff, C. A., Overwijk, W. W., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2591 · Cited by 754 · see citing works

Why do viruses cause cancer? Highlights of the first century of human tumour virology

Moore, P. S., & Chang, Y. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2961 · Cited by 752 · see citing works

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

Chang, K., & Pastan, I. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.136 · Cited by 747 · see citing works

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742 · see citing works

Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations

González-Galarza, F. F., Christmas, S. E., Middleton, D., & Jones, A. R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1128 · Cited by 720 · see citing works

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Lamers, C. H., Sleijfer, S., van Steenbergen, S. C. L., van Elzakker, P., Krimpen, B. A. V., Groot, C., Vulto, A. G., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 706 · see citing works

Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

Cameron, B., Gerry, A. B., Dukes, J. D., Harper, J. V., Kannan, V., Bianchi, F., Grand, F., Brewer, J. E., Gupta, M., Plesa, G., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006034 · Cited by 685 · see citing works

Expression of Hypoxia-Inducible Cell-Surface Transmembrane Carbonic Anhydrases in Human Cancer

Ivanov, S. V., Liao, S., Ivanova, A. V., Danilkovitch‐Miagkova, A., Tarasova, N. I., Weirich, G., Merrill, M. J., Proescholdt, M. A., Oldfield, E. H., Lee, J., et al. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64038-2 · Cited by 681 · see citing works

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M. A., Yang, S., Gress, R. E., Hakim, F. T., & Kochenderfer, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2422 · Cited by 656 · see citing works

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

Haque, T., Wilkie, G. M., Jones, M. M., Higgins, C. D., Urquhart, G., Wingate, P. J., Burns, D., McAulay, K. A., Turner, M., Bellamy, C. O. C., et al. (2007) · Blood · doi:10.1182/blood-2006-12-063008 · Cited by 646 · see citing works

IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors.

Cieri, N., Camisa, B., Cocchiarella, F., Forcato, M., Oliveira, G., Provasi, E., Bondanza, A., Bordignon, C., Peccatori, J., Ciceri, F., et al. (2013) · Blood · doi:10.1182/blood-2012-05-431718 · Cited by 611 · see citing works

Paths to stemness: building the ultimate antitumour T cell

Gattinoni, L., Klebanoff, C. A., & Restifo, N. P. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3322 · Cited by 599 · see citing works

Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers

Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay, N. E. H., Mosseri, V., Laccourreye, O., Bruneval, P., Fridman, W. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1886 · Cited by 595 · see citing works

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

Bakker, A. B. H., Schreurs, M. W. J., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., & Figdor, C. G. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.3.1005 · Cited by 589 · see citing works

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling

Paulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586 · see citing works

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

Haso, W. M., Lee, D. W., Shah, N. N., Stetler‐Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438002 · Cited by 572 · see citing works

Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

Sok, J. C., Coppelli, F. M., Thomas, S. M., Lango, M. N., Xi, S., Hunt, J. L., Freilino, M. L., Graner, M. W., Wikstrand, C. J., Bigner, D. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0913 · Cited by 488 · see citing works

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

Lee, W., Jiang, Z., Liu, J., Haverty, P. M., Guan, Y., Stinson, J., Yue, P., Zhang, Y., Pant, K. P., Bhatt, D., et al. (2010) · Nature · doi:10.1038/nature09004 · Cited by 486 · see citing works

Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2

Rosenberg, S. A., Yang, J. C., White, D. E., & Steinberg, S. M. (1998) · Annals of Surgery · doi:10.1097/00000658-199809000-00004 · Cited by 486 · see citing works

Exome sequencing identifies GRIN2A as frequently mutated in melanoma

Program, N. C. S., Wei, X., Walia, V., Lin, J., Teer, J. K., Prickett, T. D., Gartner, J. J., Davis, S. R., Stemke‐Hale, K., Davies, M. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.810 · Cited by 463 · see citing works

High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma

Klapper, J. A., Downey, S. G., Smith, F. O., Yang, J. C., Hughes, M. S., Kammula, U. S., Sherry, R. M., Royal, R. E., Steinberg, S. M., & Rosenberg, S. A. (2008) · Cancer · doi:10.1002/cncr.23552 · Cited by 433 · see citing works

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

Radvanyi, L., Bernatchez, C., Zhang, M.-Y., Fox, P., Miller, P. W., Chacon, J. A., Wu, R. C., Lizée, G., Mahoney, S. L., Alvarado, G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1177 · Cited by 423 · see citing works

Do No Harm

Jonsen, A. R. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-88-6-827 · Cited by 414 · see citing works

High number of intraepithelial cd8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer

Piersma, S. J., Jordanova, E. S., van Poelgeest, M. I. E., Kwappenberg, K. M. C., van der Hulst, J. M., Drijfhout, J. W., Melief, C. J. M., Kenter, G. G., Fleuren, G. J., Offringa, R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3388 · Cited by 414 · see citing works

Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity

Hinrichs, C., Borman, Z. A., Cassard, L., Gattinoni, L., Spolski, R., Yu, Z.-Y., Sanchez-Perez, L., Muranski, P., Kern, S., Logun, C., et al. (2009) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0907448106 · Cited by 407 · see citing works

Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease

Bollard, C. M., Aguilar, L. K., Straathof, K. C. M., Gahn, B., Huls, M. H., Rousseau, A., Sixbey, J. W., Gresik, M. V., Carrum, G., Hudson, M. M., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040890 · Cited by 387 · see citing works

Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions

Robbins, P. F., Li, Y. F., El‐Gamil, M., Zhao, Y., Wargo, J. A., Zheng, Z., Xu, H., Morgan, R. A., Feldman, S. A., Johnson, L. A., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6116 · Cited by 385 · see citing works

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.

Humphrey, P. A., Wong, A. J., Vogelstein, B., Zalutsky, M. R., Fuller, G. N., Archer, G. E., Friedman, H. S., Kwatra, M. M., Bigner, S. H., & Bigner, D. D. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4207 · Cited by 382 · see citing works

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4

Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352 · see citing works

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors

Kerkar, S. P., Goldszmid, R. S., Muranski, P. J., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 342 · see citing works

Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy

Zhou, J., Shen, X., Huang, J., Hodes, R. J., Rosenberg, S. A., & Robbins, P. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.10.7046 · Cited by 336 · see citing works

Genome-wide analysis of cancer/testis gene expression

Hofmann, O., Caballero, O. L., Stevenson, B. J., Chen, Y., Cohen, T., Chua, R. A., Maher, C. A., Panji, S., Schaefer, U., Kruger, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810777105 · Cited by 334 · see citing works

A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles

Chattopadhyay, P. K., Yu, J., & Roederer, M. (2005) · Nature Medicine · doi:10.1038/nm1293 · Cited by 321 · see citing works

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy

Hinrichs, C. S., Borman, Z. A., Gattinoni, L., Yu, Z., Burns, W. R., Huang, J., Klebanoff, C. A., Johnson, L. A., Kerkar, S. P., Yang, S., et al. (2010) · Blood · doi:10.1182/blood-2010-05-286286 · Cited by 309 · see citing works

Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma

Morgan, R. A., Johnson, L. A., Davis, J. L., Zheng, Z., Woolard, K., Reap, E. A., Feldman, S. A., Chinnasamy, N., Kuan, C.-T., Song, H., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.041 · Cited by 306 · see citing works

Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas

Marshall, J. L., Gulley, J. L., Arlen, P. M., Beetham, P. K., Tsang, K.-Y., Slack, R. S., Hodge, J. W., DOREN, S., Grosenbach, D. W., Hwang, J. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.206 · Cited by 298 · see citing works

Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus–Targeted Cytotoxic T Lymphocytes

Comoli, P., Pedrazzoli, P., Maccario, R., Basso, S., Carminati, O., Labirio, M., Schiavo, R., Secondino, S., Frasson, C., Perotti, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.6195 · Cited by 288 · see citing works

Cancer immunology—analysis of host and tumor factors for personalized medicine

Ogino, S., Galon, J., Fuchs, C. S., & Dranoff, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.122 · Cited by 284 · see citing works

Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells

Wrzesinski, C., Paulos, C. M., Kaiser, A., Muranski, P. J., Palmer, D. C., Gattinoni, L., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b88ffc · Cited by 284 · see citing works

Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.

Lal, A., Glazer, C. A., Martinson, H. M., Friedman, H. S., Archer, G. E., Sampson, J. H., & Riggins, G. J. (2002) · PubMed · Cited by 278 · see citing works

Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.

Wang, R. F., Robbins, P. F., Kawakami, Y., Kang, X. Q., & Rosenberg, S. A. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.2.799 · Cited by 270 · see citing works

The Inducible Costimulator (ICOS) Is Critical for the Development of Human T H 17 Cells

Paulos, C. M., Carpenito, C., Plesa, G., Suhoski, M. M., Varela‐Rohena, A., Golovina, T. N., Carroll, R. G., Riley, J. L., & June, C. H. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000448 · Cited by 255 · see citing works

Raising the Bar: The Curative Potential of Human Cancer Immunotherapy

Rosenberg, S. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003634 · Cited by 243 · see citing works

T-cell therapy in the treatment of post-transplant lymphoproliferative disease

Bollard, C. M., Rooney, C. M., & Heslop, H. E. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.111 · Cited by 242 · see citing works

Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

Smith, F. O., Downey, S. G., Klapper, J. A., Yang, J. C.-H., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Restifo, N. P., Levy, C. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0116 · Cited by 239 · see citing works

Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma

Dudley, M. E., Gross, C. A., Somerville, R. P. T., Hong, Y. K., Schaub, N. P., Rosati, S. F., White, D. E., Nathan, D., Restifo, N. P., Steinberg, S. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.6441 · Cited by 236 · see citing works

Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma

Louis, C. U., Straathof, K. C. M., Bollard, C. M., Ennamuri, S., Gerken, C. P., Lopez, T., Huls, M. H., Sheehan, A. M., Wu, M.-F., Liu, H., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f3cbf4 · Cited by 230 · see citing works

Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells

Inozume, T., Hanada, K., Wang, Q. J., Ahmadzadeh, M., Wunderlich, J. R., Rosenberg, S. A., & Yang, J. C.-H. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181fad2b0 · Cited by 230 · see citing works

Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

Gulley, J. L., Arlen, P. M., Tsang, K.-Y., Yokokawa, J., Palena, C., Poole, D. J., Remondo, C., Cereda, V., Jones, J. L., Pazdur, M. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0126 · Cited by 228 · see citing works

Type 17 CD8+ T cells display enhanced antitumor immunity

Hinrichs, C. S., Kaiser, A., Paulos, C. M., Cassard, L., Sanchez-Perez, L. A., Heemskerk, B., Wrzesinski, C., Borman, Z. A., Muranski, P. J., & Restifo, N. P. (2009) · Blood · doi:10.1182/blood-2009-02-203935 · Cited by 226 · see citing works

Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer

Yao, X., Ahmadzadeh, M., Lu, Y., Liewehr, D. J., Dudley, M. E., Liu, F., Schrump, D. S., Steinberg, S. M., Rosenberg, S. A., & Robbins, P. F. (2012) · Blood · doi:10.1182/blood-2011-10-386482 · Cited by 206 · see citing works

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells

Wrzesinski, C., Paulos, C. M., Gattinoni, L., Palmer, D. C., Kaiser, A., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30414 · Cited by 202 · see citing works

Live-cell assay to detect antigen-specific CD4+ T-cell responses by CD154 expression

Chattopadhyay, P. K., Yu, J., & Roederer, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.1 · Cited by 201 · see citing works

Carbonic Anhydrase IX Is Not an Independent Predictor of Outcome for Patients With Clear Cell Renal Cell Carcinoma

Leibovich, B. C., Sheinin, Y. M., Lohse, C. M., Thompson, R. H., Cheville, J. C., Závada, J., & Kwon, E. D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1087 · Cited by 197 · see citing works

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)

Chu, C. T., Everiss, K. D., Wikstrand, C. J., Batra, S. K., Kung, H.-J., & Bigner, D. D. (1997) · Biochemical Journal · doi:10.1042/bj3240855 · Cited by 184 · see citing works

TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients

Kvistborg, P., Shu, C. J., Heemskerk, B., Fankhauser, M., Thrue, C. A., Toebes, M., van Rooij, N., Linnemann, C., van Buuren, M. M., Urbanus, J. H. M., et al. (2012) · OncoImmunology · doi:10.4161/onci.18851 · Cited by 178 · see citing works

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

Ellebæk, E., Iversen, T. Z., Junker, N., Donia, M., Engell-Noerregaard, L., Met, Ö., Hölmich, L. R., Andersen, R. S., Hadrup, S. R., Andersen, M. H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-169 · Cited by 172 · see citing works

Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells

van Baren, N., Bonnet, M.-C., Dréno, B., Khammari, A., Dorval, T., Piperno-Neumann, S., Líénard, D., Speiser, D. E., Marchand, M., Brichard, V. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.375 · Cited by 172 · see citing works

Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.

Seung, L. P., Rowley, D. A., Dubey, P., & Schreiber, H. W. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6254 · Cited by 170 · see citing works

Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy

Itzhaki, O., Hovav, E., Ziporen, Y., Levy, D., Kubi, A., Zikich, D., Hershkovitz, L., Treves, A. J., Shalmon, B., Zippel, D. B., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318209c94c · Cited by 170 · see citing works

Analysis of the genome to personalize therapy for melanoma

Davies, M. A., & Samuels, Y. (2010) · Oncogene · doi:10.1038/onc.2010.323 · Cited by 167 · see citing works

Use of tumour-responsive T cells as cancer treatment

Disis, M. L., Bernhard, H., & Jaffee, E. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60404-9 · Cited by 164 · see citing works

Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma

Palavalli, L. H., Prickett, T. D., Wunderlich, J. R., Wei, X., Burrell, A. S., Porter-Gill, P. A., Davis, S. R., Wang, C., Cronin, J. C., Agrawal, N., et al. (2009) · Nature Genetics · doi:10.1038/ng.340 · Cited by 161 · see citing works

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming

Atanackovic, D., Altorki, N. K., Cao, Y., Ritter, E., Ferrara, C. A., Ritter, G., Hoffman, E. W., Bokemeyer, C., Old, L. J., & Gnjatic, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707140104 · Cited by 156 · see citing works

Modulation by IL-2 of CD70 and CD27 Expression on CD8+ T Cells: Importance for the Therapeutic Effectiveness of Cell Transfer Immunotherapy

Huang, J., Kerstann, K. W., Ahmadzadeh, M., Li, Y. F., El‐Gamil, M., Rosenberg, S. A., & Robbins, P. F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7726 · Cited by 154 · see citing works

Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression

Lu, Y., Yao, X., Li, Y. F., El‐Gamil, M., Dudley, M. E., Yang, J. C.-H., Almeida, J. R., Douek, D. C., Samuels, Y., Rosenberg, S. A., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202830 · Cited by 153 · see citing works

Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma

Prickett, T. D., Wei, X., Cárdenas-Navia, I., Teer, J. K., Lin, J., Walia, V., Gartner, J. J., Jiang, J., Cherukuri, P. F., Molinolo, A. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.950 · Cited by 150 · see citing works

FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions

Ahmadzadeh, M., Felipe-Silva, A., Heemskerk, B., Powell, D. J., Wunderlich, J. R., Merino, M. J., & Rosenberg, S. A. (2008) · Blood · doi:10.1182/blood-2008-06-163048 · Cited by 141 · see citing works

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

Palmer, D. C., Chan, C., Gattinoni, L., Wrzesinski, C., Paulos, C. M., Hinrichs, C. S., Powell, D. J., Klebanoff, C. A., Finkelstein, S. E., Fariss, R. N., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710929105 · Cited by 130 · see citing works

Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells

Parkhurst, M. R., Joo, J. S., Riley, J. P., Yu, Z., Li, Y., Robbins, P. F., & Rosenberg, S. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1638 · Cited by 122 · see citing works

Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response

Rosenberg, S. A., Yang, J., White, D. E., & Steinberg, S. M. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68669-7 · Cited by 116 · see citing works

Epstein–Barr virus and carcinogenesis: beyond Burkitt's lymphoma

Shah, K. S., & Young, L. S. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03033.x · Cited by 115 · see citing works

Constitutive EGFR signaling confers a motile phenotype to neural stem cells

Boockvar, J. A., Kapitonov, D., Kapoor, G. S., Schouten, J. W., Counelis, G. J., Bögler, O., Snyder, E. Y., McIntosh, T. K., & O’Rourke, D. M. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2003.09.011 · Cited by 114 · see citing works

Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: Prognostic impact may depend on type of treatment and stage of disease

Distel, L. V., Fickenscher, R., Dietel, K., Hung, A., Iro, H., Zenk, J., Nkenke, E., Büttner, M., Niedobitek, G., & Grabenbauer, G. G. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2009.05.640 · Cited by 110 · see citing works

Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?

Fojo, T., & Parkinson, D. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1277 · Cited by 110 · see citing works

Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy

Turcotte, S., Gros, A., Hogan, K., Tran, E., Hinrichs, C. S., Wunderlich, J. R., Dudley, M. E., & Rosenberg, S. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300538 · Cited by 107 · see citing works

Expression of CD27 on Murine Hematopoietic Stem and Progenitor Cells

Wiesmann, A., Phillips, R. L., Mojica-Henshaw, M. P., Pierce, L., Searles, A. E., Spangrude, G. J., & Lemischka, I. R. (2000) · Immunity · doi:10.1016/s1074-7613(00)80172-7 · Cited by 103 · see citing works

Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

Kelly, R. J., Sharon, E., Pastan, I. H., & Hassan, R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0454 · Cited by 102 · see citing works

Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor

Ullenhag, G. J., Frödin, J., Jeddi‐Tehrani, M., Strigård, K., Eriksson, E., Samanci, A., Choudhury, A., Nilsson, B., Rossmann, E. D., Mosolits, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0706 · Cited by 92 · see citing works

Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma

Gros, A., Turcotte, S., Wunderlich, J. R., Ahmadzadeh, M., Dudley, M. E., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1108 · Cited by 86 · see citing works

Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA‐DQ and –DP as a restriction element

Piersma, S. J., Welters, M. J. P., van der Hulst, J. M., Kloth, J. N., Kwappenberg, K. M. C., Trimbos, B. J. B. M. Z., Melief, C. J. M., Hellebrekers, B. W. J., Fleuren, G. J., Kenter, G. G., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23162 · Cited by 85 · see citing works

An Unexpectedly Large Polyclonal Repertoire of HPV-Specific T Cells Is Poised for Action in Patients with Cervical Cancer

van Steenwijk, P. J. D. V., Heusinkveld, M., Ramwadhdoebé, T. H., Löwik, M. J. G., van der Hulst, J. M., Goedemans, R., Piersma, S. J., Kenter, G. G., & van der Burg, S. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4299 · Cited by 84 · see citing works

Infiltration by immunocompetent cells in early stage invasive carcinoma of the uterine cervix: a prognostic study

Bethwaite, P. B., Holloway, L., Thornton, A., & Delahunt, B. (1996) · Pathology · doi:10.1080/00313029600169274 · Cited by 82 · see citing works

A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells

Wagner, H., Bollard, C. M., Vigouroux, S., Huls, M. H., Anderson, R. W., Prentice, H. G., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700664 · Cited by 76 · see citing works

Immune activation modulates hematopoiesis through interactions between CD27 and CD70

Nolte, M. A., Arens, R., van Os, R. P., van Oosterwijk, M. F., Hooibrink, B., van Lier, R. A. W., & van Oers, M. H. J. (2005) · Nature Immunology · doi:10.1038/ni1174 · Cited by 74 · see citing works

Collapse of the Tumor Stroma is Triggered by IL-12 Induction of Fas

Kerkar, S. P., Leonardi, A. J., van Panhuys, N., Zhang, L., Yu, Z., Crompton, J. G., Pan, J. H., Palmer, D. C., Morgan, R. A., Rosenberg, S. A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.58 · Cited by 64 · see citing works

Mutational and Functional Analysis Reveals ADAMTS18 Metalloproteinase as a Novel Driver in Melanoma

Wei, X., Prickett, T. D., Viloria, C. G., Molinolo, A., Lin, J., Cárdenas-Navia, I., Cruz, P., Rosenberg, S. A., Davies, M. A., Gershenwald, J. E., et al. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0262 · Cited by 54 · see citing works

Tumor-infiltrating lymphocytes from nonrenal urological malignancies

Haas, G. P., Solomon, D., & Rosenberg, S. A. (1990) · Cancer Immunology Immunotherapy · doi:10.1007/bf01786883 · Cited by 51 · see citing works

The development of new cancer therapies based on the molecular identification of cancer regression antigens.

Rosenberg, S. A. (2006) · PubMed · Cited by 44 · see citing works

Delving into somatic variation in sporadic melanoma

Walia, V., Mu, E. W., Lin, J., & Samuels, Y. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00976.x · Cited by 41 · see citing works

Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma

Gartner, J. J., Davis, S. R., Wei, X., Lin, J., Trivedi, N. S., Teer, J. K., Program, N. C. S., Meltzer, P. S., Rosenberg, S. A., & Samuels, Y. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-505 · Cited by 37 · see citing works

Evaluation of γ-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical Application

Zhang, L., Feldman, S. A., Zheng, Z., Chinnasamy, N., Xu, H., Nahvi, A. V., Dudley, M. E., Rosenberg, S. A., & Morgan, R. A. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31825898e8 · Cited by 33 · see citing works

with Chemotherapy-Refractory Acute Lymphoblastic Leukemia CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults

Brentjens, R. J. (2013) · Cited by 29 · see citing works

Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma and Normal Tissues: Experiences From (Radio) Immunotherapy

Brouwers, A. H., Mulders, P. F. A., & Oyen, W. J. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.6073 · Cited by 12 · see citing works

Do no harm

(2013) · Nature Biotechnology · doi:10.1038/nbt.2587 · Cited by 7 · see citing works

Untitled work

Hsing (1996) · doi:10.1002/(sici)1097-0215(19960208)65:4 · Cited by 1 · see citing works

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · see citing works

Molecular and genetic properties of tumors associated with local immune cytolytic activity

Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · see citing works

Chimeric antigen receptor T-cell therapy—assessment and management of toxicities

Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438 · see citing works

CD4+ T cell help in cancer immunology and immunotherapy

Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585 · see citing works

Cancer immunotherapy: the beginning of the end of cancer?

Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,192 · see citing works

Cytokines in clinical cancer immunotherapy

Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberría, I., Aznar, M. A., Perez‐Gracia, J. L., Rodriguez-Ruiz, M. E., Ponz‐Sarvisé, M., Álvarez, E. C., & Melero, I. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,190 · see citing works

Therapeutic cancer vaccines

Melief, C. J. M., van Hall, T., Arens, R., OSSENDORP, F. A., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,182 · see citing works

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

Duhen, T., Duhen, R., Montler, R., Moses, J., Moudgil, T., de Miranda, N. F., Goodall, C. P., Blair, T. C., Fox, B. A., McDermott, J. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05072-0 · Cited by 938 · see citing works

Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment

Dai, Y., Xu, C., Sun, X., & Chen, X. S. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 931 · see citing works

Toxicity and management in CAR T-cell therapy

Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.11 · Cited by 892 · see citing works

TRUCKs: the fourth generation of CARs

Chmielewski, M. M., & Abken, H. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1046430 · Cited by 750 · see citing works

Navigating metabolic pathways to enhance antitumour immunity and immunotherapy

Li, X., Wenes, M., Romero, P. J., Huang, S. C., Fendt, S., & Ho, P. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0203-7 · Cited by 745 · see citing works

Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells

Stevanović, S., Draper, L. M., Langhan, M. M., Campbell, T. E., Kwong, M. L. M., Wunderlich, J. R., Dudley, M. E., Yang, J. C., Sherry, R. M., Kammula, U. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9093 · Cited by 682 · see citing works

Improving cancer immunotherapy through nanotechnology

Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628 · see citing works

Cancer Neoantigens

Schumacher, T. N., Scheper, W., & Kvistborg, P. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053402 · Cited by 578 · see citing works

Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer

Picard, E., Verschoor, C. P., Grace, W. K., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00369 · Cited by 520 · see citing works

Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18

Hu, B., Ren, J., Luo, Y., Keith, B., Young, R. M., Scholler, J., Zhao, Y., & June, C. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.002 · Cited by 504 · see citing works

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy

Durgeau, A., Virk, Y., Corgnac, S., & Mami‐Chouaib, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00014 · Cited by 495 · see citing works

Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells

Chen, Q., Hu, Q., Dukhovlinova, E., Chen, G., Ahn, S., Wang, C., Ogunnaike, E. A., Ligler, F. S., Dotti, G., & Gu, Z. (2019) · Advanced Materials · doi:10.1002/adma.201900192 · Cited by 469 · see citing works

Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia

Wang, Q., Wang, Y., Lv, H., Han, Q., Fan, H., Guo, B., Wang, L.-L., & Han, W. (2014) · Molecular Therapy · doi:10.1038/mt.2014.164 · Cited by 418 · see citing works

Tumor microenvironment: barrier or opportunity towards effective cancer therapy

Tiwari, A., Trivedi, R., & Lin, S. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00866-3 · Cited by 391 · see citing works

Engineered Cell‐Membrane‐Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity

Jiang, Y., Krishnan, N., Zhou, J., Chekuri, S., Wei, X., Kroll, A. V., Yu, C. L., Duan, Y., Gao, W., Fang, R. H., et al. (2020) · Advanced Materials · doi:10.1002/adma.202001808 · Cited by 371 · see citing works

Mechanisms regulating T-cell infiltration and activity in solid tumors

Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369 · see citing works

Combinational strategy for high-performance cancer chemotherapy

Qin, S., Cheng, Y., Lei, Q., Zhang, A., & Zhang, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.027 · Cited by 301 · see citing works

Tissue-resident memory T cells at the center of immunity to solid tumors

Amsen, D., van Gisbergen, K. P. J. M., Hombrink, P., & van Lier, R. A. W. (2018) · Nature Immunology · doi:10.1038/s41590-018-0114-2 · Cited by 278 · see citing works

Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids

Seet, C. S., He, C., Bethune, M. T., Li, S., Chick, B. Y., Gschweng, E. H., Zhu, Y., Kim, K., Kohn, D. B., Baltimore, D., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4237 · Cited by 272 · see citing works

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

Maus, M. V., & June, C. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1433 · Cited by 269 · see citing works

Driving gene-engineered T cell immunotherapy of cancer

Johnson, L. A., & June, C. H. (2016) · Cell Research · doi:10.1038/cr.2016.154 · Cited by 263 · see citing works

Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy

Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250 · see citing works

Immunotherapy of Prostate Cancer: Facts and Hopes

Bilušić, M., Madan, R. A., & Gulley, J. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0019 · Cited by 248 · see citing works

Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?

Badalamenti, G., Fanale, D., Incorvaia, L., Barraco, N., Listì, A., Maragliano, R., Vincenzi, B., Calò, V., Iovanna, J., Bazan, V., et al. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.01.013 · Cited by 245 · see citing works

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

Tian, H., Cao, J., Li, B., Nice, E. C., Mao, H., Zhang, Y., & Huang, C. (2023) · Bone Research · doi:10.1038/s41413-023-00246-z · Cited by 239 · see citing works

The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma

Heymann, M.-F., Lézot, F., & Heymann, D. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.011 · Cited by 233 · see citing works

Cancer stem cells: landscape, challenges and emerging therapeutic innovations

Lee, H., Kim, B., Park, J., Park, S., Yoo, G., Yum, S., Kang, W., Lee, J., Youn, H., & Youn, B. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02360-2 · Cited by 228 · see citing works

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Dagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., Chauhan, R., Dagar, M., Mirza, S., Bagga, P., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04292-3 · Cited by 218 · see citing works

Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity

Grabovska, Y., Mackay, A. G., O’Hare, P., Crosier, S., Finetti, M. A., Schwalbe, E. C., Pickles, J. C., Fairchild, A. R., Avery, A., Cockle, J. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18070-y · Cited by 210 · see citing works

CRISPR-Cas9: a new and promising player in gene therapy

Xiao-Jie, L., Hui-Ying, X., Zun-Ping, K., Jin-Lian, C., & Li-Juan, J. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102968 · Cited by 200 · see citing works

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation

Masucci, G. V., Cesano, A., Hawtin, R. E., Janetzki, S., Zhang, J., Kirsch, I. R., Dobbin, K. K., Alvarez, J. D., Robbins, P. B., Selvan, S. R., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0178-1 · Cited by 200 · see citing works

Cancer immunotherapy: Challenges and limitations

Taefehshokr, S., Parhizkar, A., Hayati, S., Mousapour, M., Mahmoudpour, A., Eid, L. E., Rahmanpour, D., Fattahi, S., Shabani, H., & Taefehshokr, N. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153723 · Cited by 198 · see citing works

Biomedical polymers: synthesis, properties, and applications

Chen, W., Chen, Q., Chen, Q., Cui, C., Duan, S., Kang, Y., Liu, Y., Liu, Y., Muhammad, W., Shao, S., et al. (2022) · Science China Chemistry · doi:10.1007/s11426-022-1243-5 · Cited by 191 · see citing works

Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6

Draper, L. M., Kwong, M. L. M., Gros, A., Stevanović, S., Tran, E., Kerkar, S. P., Raffeld, M. A., Rosenberg, S. A., & Hinrichs, C. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3341 · Cited by 184 · see citing works

Reversal of tumor immune inhibition using a chimeric cytokine receptor.

Leen, A., Sukumaran, S., Watanabe, N., Mohammed, S., Keirnan, J., Yanagisawa, R., Anurathapan, U., Rendon, D. A., Heslop, H., Rooney, C., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.47 · Cited by 171 · see citing works

CAR T Cell Therapy: A Game Changer in Cancer Treatment

Almåsbak, H., Aarvak, T., & Vemuri, M. C. (2016) · Journal of Immunology Research · doi:10.1155/2016/5474602 · Cited by 182 · see citing works

Metal-free bioorthogonal click chemistry in cancer theranostics

Wu, D., Yang, K., Zhang, Z., Feng, Y., Rao, L., Chen, X. S., & Yu, G. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00451d · Cited by 177 · see citing works

Recent advances in developing active targeting and multi-functional drug delivery systems via bioorthogonal chemistry

Yi, W., Xiao, P., Liu, X., Zhao, Z., Sun, X., Wang, J., Zhou, L., Wang, G., Cao, H., Wang, D., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01250-1 · Cited by 173 · see citing works

Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model

Jin, B. E., Campbell, T. E., Draper, L. M., Stevanović, S., Weißbrich, B., Yu, Z., Restifo, N. P., Rosenberg, S. A., Trimble, C. L., & Hinrichs, C. S. (2018) · JCI Insight · doi:10.1172/jci.insight.99488 · Cited by 171 · see citing works

Direct Cell Radiolabeling for in Vivo Cell Tracking with PET and SPECT Imaging

Gawne, P. J., Man, F., Blower, P. J., & de Rosales, R. T. M. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00767 · Cited by 168 · see citing works

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition

Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 162 · see citing works

Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies

Gurusamy, D., Henning, A. N., Yamamoto, T. N., Yu, Z., Zacharakis, N., Krishna, S., Kishton, R. J., Vodnala, S. K., Eidizadeh, A., Jia, L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.004 · Cited by 159 · see citing works

Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells

Xiong, W., Chen, Y., Kang, X., Chen, Z., Zheng, P., Hsu, Y.-H., Jang, J. H., Qin, L., Liu, H., Dotti, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.020 · Cited by 154 · see citing works

Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma

Mina, M., Boldrini, R., Citti, A., Romania, P., D’Alicandro, V., Ioris, M. A. D., Castellano, A., Furlanello, C., Locatelli, F., & Fruci, D. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1019981 · Cited by 153 · see citing works

Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors

Chheda, Z. S., Sharma, R. K., Jala, V. R., Luster, A. D., & Haribabu, B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502376 · Cited by 153 · see citing works

In vivo chimeric antigen receptor (CAR)-T cell therapy

Bot, A., Scharenberg, A. M., Friedman, K. M., Guey, L. T., Hofmeister, R., Andorko, J. I., Klichinsky, M., Neumann, F., Shah, J. V., Swayer, A. J., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01291-5 · Cited by 153 · see citing works

Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens

Kalaora, S., Barnea, E., Merhavi-Shoham, E., Qutob, N., Teer, J. K., Shimony, N., Schachter, J., Rosenberg, S. A., Besser, M. J., Admon, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6960 · Cited by 148 · see citing works

Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

Etxeberría, I., Bolaños, E., Quetglas, J. I., Gros, A., Villanueva, A., Palomero, J., Sánchez-Paulete, A. R., Piulats, J. M., Matías‐Guiu, X., Olivera, I., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.006 · Cited by 145 · see citing works

Current Advances in T-Cell-Based Cancer Immunotherapy

Wang, M., Yin, B., Wang, H. Y., & Wang, R. (2014) · Immunotherapy · doi:10.2217/imt.14.86 · Cited by 141 · see citing works

Tumour microenvironment responsive nanoconstructs for cancer theranostic

Gulzar, A., Xu, J., Wang, C., He, F., Yang, D., Gai, S., Yang, P., Lin, J., Jin, D., & Xing, B. (2019) · Nano Today · doi:10.1016/j.nantod.2019.03.007 · Cited by 140 · see citing works

Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma

Inoue, H., Park, J., Kiyotani, K., Zewde, M. G., Miyashita, A., Jinnin, M., Kiniwa, Y., Okuyama, R., Tanaka, R., Fujisawa, Y., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1204507 · Cited by 134 · see citing works

In Response to Precision Medicine: Current Subcellular Targeting Strategies for Cancer Therapy

Li, Z., Zou, J., & Chen, X. S. (2022) · Advanced Materials · doi:10.1002/adma.202209529 · Cited by 132 · see citing works

HIV-specific CD8+ T cells and HIV eradication

Jones, R. B., & Walker, B. D. (2016) · Journal of Clinical Investigation · doi:10.1172/jci80566 · Cited by 131 · see citing works

Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities

Jiang, X., Jiang, X., Liu, M., Xing, H., Wang, Z., Huang, L., Mellor, A. L., Wang, W., & Wu, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.017 · Cited by 129 · see citing works

The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review

Abdul‐Rahman, T., Ghosh, S., Badar, S. M., Nazir, A., Bamigbade, G. B., Aji, N., Roy, P., kachani, H., Garg, N. K., Lawal, L., et al. (2024) · European journal of medical research · doi:10.1186/s40001-024-01711-z · Cited by 125 · see citing works

The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity

Helsen, C. W., Hammill, J. A., Lau, V. W. C., Mwawasi, K. A., Afsahi, A., Bezverbnaya, K., Newhook, L., Hayes, D. L., Aarts, C. W., Bojović, B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05395-y · Cited by 123 · see citing works

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy

Wang, P., Chen, Y., & Wang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672677 · Cited by 122 · see citing works

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting

Slaney, C. Y., von Scheidt, B., Davenport, A. J., Beavis, P. A., Westwood, J. A., Mardiana, S., Tscharke, D. C., Ellis, S. L., Prince, H. M., Trapani, J. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1860 · Cited by 121 · see citing works

Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity

Liu, L., Patel, B., Ghanem, M. H., Bundoc, V., Zheng, Z., Morgan, R. A., Rosenberg, S. A., Dey, B., & Berger, E. A. (2015) · Journal of Virology · doi:10.1128/jvi.00474-15 · Cited by 117 · see citing works

CXCR6 is required for antitumor efficacy of intratumoral CD8 + T cell

Wang, B., Wang, Y., Sun, X., Deng, G., Huang, W., Wu, X., Gu, Y., Tian, Z., Fan, Z., Xu, Q., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003100 · Cited by 117 · see citing works

CAR T‐cell therapy for pancreatic cancer

DeSelm, C. J., Tano, Z. E., Varghese, A. M., & Adusumilli, P. S. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24627 · Cited by 114 · see citing works

CAR-T cells and BiTEs in solid tumors: challenges and perspectives

Edeline, J., Houot, R., Marabelle, A., & Alcantara, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01067-5 · Cited by 114 · see citing works

You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy

Pfefferle, A., & Huntington, N. D. (2020) · Cancers · doi:10.3390/cancers12030706 · Cited by 113 · see citing works

Cost of decentralized CAR T‐cell production in an academic nonprofit setting

Ran, T., Eichmüller, S. B., Schmidt, P., & Schlander, M. (2020) · International Journal of Cancer · doi:10.1002/ijc.33156 · Cited by 113 · see citing works

The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis

Roufas, C., Chasiotis, D., Makris, A., Efstathiades, C., Dimopoulos, C., & Zaravinos, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00027 · Cited by 111 · see citing works

Dendritic cells based immunotherapy.

Shang, N., Figini, M., Shangguan, J., Wang, B., Sun, C., Pan, L., Ma, Q., & Zhang, Z. (2017) · PubMed Central · Cited by 109 · see citing works

Rare cancers: a sea of opportunity

Boyd, N., Dancey, J. E., Gilks, C. B., & Huntsman, D. D. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00386-1 · Cited by 107 · see citing works

Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy

Sayour, E. J., Grippin, A., Leon, G. D., Stover, B. D., Rahman, M., Karachi, A., Wummer, B. M., Moore, G. L., Castillo‐Caro, P., Fredenburg, K. M., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02179 · Cited by 107 · see citing works

CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond

Chang, Z., & Chen, Y. Y. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.002 · Cited by 104 · see citing works

The role of cancer stem cells in the modulation of anti-tumor immune responses

Maccalli, C., Rasul, K. I., Elawad, M., & Ferrone, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.006 · Cited by 104 · see citing works

A comprehensive review on traditional uses, chemical compositions, pharmacology properties and toxicology of Tetrastigma hemsleyanum

Ji, T., Ji, W. W., Wang, J., Chen, H. J., Peng, X. X., Cheng, K., Qiu, D., & Yang, W. J. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113247 · Cited by 104 · see citing works

Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes

Yeh, W.-I., Seay, H. R., Newby, B. N., Posgai, A. L., Moniz, F. B., Michels, A. W., Mathews, C. E., Bluestone, J. A., & Brusko, T. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01313 · Cited by 103 · see citing works

The Pharmacology of T Cell Therapies

Milone, M. C., & Bhoj, V. G. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.010 · Cited by 103 · see citing works

Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?

Al‐Khadairi, G., & Decock, J. V. (2019) · Cancers · doi:10.3390/cancers11070984 · Cited by 102 · see citing works

Starved and Asphyxiated: How Can CD8+ T Cells within a Tumor Microenvironment Prevent Tumor Progression

Zhang, Y., & Ertl, H. C. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00032 · Cited by 100 · see citing works

Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8 + T-cell axis

Brackett, C. M., Kojouharov, B., Veith, J. M., Greene, K. F., Burdelya, L. G., Gollnick, S. O., Abrams, S. I., & Gudkov, A. V. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521359113 · Cited by 100 · see citing works

Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4 + T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy

Liu, B., Zou, F., Lu, L., Chen, C., He, D., Zhang, X., Tang, X., Liu, C., Li, L., & Zhang, H. (2016) · Journal of Virology · doi:10.1128/jvi.00852-16 · Cited by 100 · see citing works

Ten‐year update of the international registry on cytokine‐induced killer cells in cancer immunotherapy

Zhang, Y., & Schmidt‐Wolf, I. G. H. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29827 · Cited by 99 · see citing works

Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity

Sánchez-Paulete, A. R., Mateus-Tique, J., Mollaoglu, G., Nielsen, S. R., Marks, A., Lakshmi, A., Khan, J. A., Wilk, C. M., Pia, L., Baccarini, A., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-1075 · Cited by 98 · see citing works

STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice

Wang, Z., & Celis, E. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1713-5 · Cited by 97 · see citing works

Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies

Wang, X., & Rivière, I. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2014.81 · Cited by 96 · see citing works

CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges

Yi, L., & Li, J. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.002 · Cited by 96 · see citing works

Immunotherapy of cancers comes of age

Yousefi, H., Yuan, J. D., Keshavarz‐Fathi, M., Murphy, J. F., & Rezaei, N. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1366315 · Cited by 96 · see citing works

Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy

Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 94 · see citing works

Adoptive T-cell therapy for cancer: the era of engineered T cells

Bonini, C., & Mondino, A. (2015) · European Journal of Immunology · doi:10.1002/eji.201545552 · Cited by 93 · see citing works

Promising approaches in cancer immunotherapy

Taefehshokr, N., Baradaran, B., Baghbanzadeh, A., & Taefehshokr, S. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.11.010 · Cited by 93 · see citing works

Translational research in oncology—10 years of progress and future prospects

Doroshow, J. H., & Kummar, S. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.158 · Cited by 89 · see citing works

Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy

Maccalli, C., Parmiani, G., & Ferrone, S. (2017) · Immunological Investigations · doi:10.1080/08820139.2017.1280051 · Cited by 88 · see citing works

The role of stem cells in small-cell lung cancer: Evidence from chemoresistance to immunotherapy

Guo, W., Qiao, T., & Li, T. X. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.006 · Cited by 86 · see citing works

Injectable Biomimetic Hydrogels as Tools for Efficient T Cell Expansion and Delivery

Weiden, J., Voerman, D., Dölen, Y., Das, R. K., van Duffelen, A., Hammink, R., Eggermont, L. J., Rowan, A. E., Tel, J., & Figdor, C. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02798 · Cited by 84 · see citing works

Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer

Zheng, Y., Dou, Y., Duan, L., Cong, C., Gao, A., Lai, Q., & Sun, Y. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.02.003 · Cited by 83 · see citing works

CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia

Bonifant, C. L., Szöőr, Á., Torres, D., Joseph, N. P., Velasquez, M. P., Iwahori, K., Gaikwad, A. S., Nguyen, P., Arber, C., Song, X., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.116 · Cited by 83 · see citing works

Thyroid dysfunctions secondary to cancer immunotherapy

Chalan, P., Dalmazi, G. D., Pani, F., Remigis, A. D., Corsello, A., & Caturegli, P. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0778-8 · Cited by 81 · see citing works

Adoptive Cell Therapy for Metastatic Melanoma

Merhavi-Shoham, E., Itzhaki, O., Markel, G., Schachter, J., & Besser, M. J. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000240 · Cited by 61 · see citing works

Adoptive T-Cell Therapy for Cancer

Yang, J. C.-H., & Rosenberg, S. A. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.006 · Cited by 205 · see citing works

Adoptive T-cell Transfer in Melanoma

Itzhaki, O., Levy, D., Zikich, D., Treves, A. J., Markel, G., Schachter, J., & Besser, M. J. (2012) · Immunotherapy · doi:10.2217/imt.12.143 · Cited by 23 · see citing works

Adoptive Cell Transfer for Patients with Metastatic Melanoma: The Potential and Promise of Cancer Immunotherapy

Phan, G. Q., & Rosenberg, S. A. (2013) · Cancer Control · doi:10.1177/107327481302000406 · Cited by 106 · see citing works

Abstract IA19: Curative potential of T-cell immunotherapy for cancer

Rosenberg, S. A. (2015) · Cancer Immunology Research · doi:10.1158/2326-6074.tumimm14-ia19